news

Transcript: Q3 2026 investor update from EXOZ

Written by eXoZymes | November 19, 2026

 

Speakers: Michael Heltzen, Chief Executive Officer · Dr. Tyler Korman, Chief Scientific Officer · Damien Perriman, Chief Commercial Officer · Fouad Nawaz, VP of Finance

 

Forward-looking statements

Before we begin, today's remarks include forward-looking statements, including statements about our technology transfer to Curia, our GRAS determination, our planned human study, our commercialization plans for NCT, now called Tyferyn, our pipeline, and our financial condition. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.

Those risks are described in our Annual Report on Form 10-K for 2025, our Quarterly Report on Form 10-Q for the third quarter, which we filed on November 13, as well as our other SEC filings.

We undertake no obligation to update these statements except as required by law. Statements about Tyferyn have not been evaluated by the FDA. Tyferyn is not intended to diagnose, treat, cure, or prevent any disease.

 

Welcome

Good afternoon, and welcome to the eXoZymes third quarter 2026 investor update. I'm Michael Heltzen, CEO of eXoZymes. With me today are Dr. Tyler Korman, our Chief Scientific Officer; Damien Perriman, our Chief Commercial Officer; and Fouad Nawaz, our VP of Finance.

As many of you know, we filed a registration statement on Form S-1 with the SEC. The registration statement has not yet become effective, and the securities it covers may not be sold, nor may offers to buy be accepted, before it becomes effective.

Nothing on today's call is an offer to sell or a solicitation of an offer to buy any securities. Because we are in registration, we will not be discussing the proposed offering today, and for the same reason we will not be holding a Q&A session on this call, as we otherwise usually do. The registration statement is available on the SEC's website.

With that, let me start with where we stand.

 

Strategy and quarter overview

Michael Heltzen: Our mission is to unlock valuable molecules that only nature has been able to make until now, for use in health, longevity, and other specialty applications.

Many of these molecules are too rare in nature to extract economically and too hard to synthesize. Our platform uses exozymes, that is, enzymes our scientists engineer with the help of AI and lab methods, to run biochemistry outside of living cells and convert abundant feedstocks into these valuable molecules at high purity.

We apply the platform through a repeatable playbook with four stages:

  1. Molecule prospecting, where we screen potential ideas.
  2. A molecule incubator for proof of concept.
  3. A product accelerator that produces a technology transfer package.
  4. Commercialization, which brings the product to market and to first revenue.
  5. A safety evaluation by an independent expert panel to support a self-affirmed GRAS determination for market entry, targeted for the second quarter of 2027.
  6. A single-dose, IND-exempt human pharmacokinetic study in healthy adults, targeted for the first quarter of 2027. This will confirm absorption and set the dose level for future studies.
  7. Formulation work and targeted studies to substantiate additional structure/function claims, which have already happened and will be ongoing.

For each molecule, we intend to pursue a fast-to-market route first, typically as a supplement ingredient, and then a pharmaceutical opportunity through engineered, new-to-nature analogs that we would like to develop together with biotech and pharma partners.

NCT, now Tyferyn, is our lead program and the first we are taking through the full playbook. The main operational milestones of the period:

  • In July, we were selected for the U.S. Department of Energy's Genesis Mission grant to build AI-powered digital twins of cell-free biomanufacturing with Lawrence Berkeley National Laboratory.
  • In September, we selected Curia Global as our commercial-scale manufacturing partner for NCT, and the technology transfer to Curia began in this fourth quarter.
  • We are in the process of registering the trademark Tyferyn for our NCT products and branding.

As a reminder, our strategy has five parts: first, bring NCT to market across different channels; second, create a pharmaceutical analog option from the NCT biosolution; third, repeat the playbook with the next molecules in line, starting with the non-intoxicating cannabinoids; fourth, stay capital-light by manufacturing through contract manufacturing partners rather than building our own facilities; and fifth, keep applying for non-dilutive funding.

As always, please read our SEC filings to get a complete picture of eXoZymes. And note that our November 2026 S-1 prospectus is not yet effective and will be updated soon. Please read the full and final version.

And now I'll hand it over to Tyler for the science.

 

Science, pipeline and intellectual property

Dr. Tyler Korman: Thank you, Michael. Let me start with how our platform works. We make each enzyme in an industrial microbial host such as E. coli or yeast, then run the enzymes together outside the cell, typically as a single one-pot cascade, and isolate the target molecule. Without a cell to keep alive, yields are not capped by growth or side products, and each pathway can be tuned for a single target. I began this work with co-founders Jim Bowie and Paul Opgenorth at UCLA over a decade ago, and since then we have built a library of thousands of engineered exozymes.

We believe our approach offers advantages in speed and cost and in access to rare molecules, although each still has to be proven at commercial scale and over time.

Now to NCT, which is now called Tyferyn. NCT is a rare plant compound found in black peppercorns and other plants at less than 15 parts per million. Published research has identified NCT as the first potent, selective activator of HNF4α, a nuclear receptor that regulates genes controlling mitochondrial function, fat metabolism, and gut barrier integrity, and a target with no approved therapy.

So what does our process data show for NCT? In January 2026, our independent partner, Cayman Chemical, ran our patent-pending NCT process in a 100-liter reactor. That run produced 535 grams of NCT at 99.6% purity and converted 99% of the feedstock into product.

Since that pilot run, we've optimized the process to produce approximately 67% more NCT per liter of reactor volume, with a reaction rate approximately five times faster. We've also moved it onto unit operations used by commercial manufacturers. We estimate these changes will increase productivity approximately tenfold compared with the pilot process. But I want to be precise here: that is an internal estimate, and it has not been demonstrated at commercial scale.

Next, let's look at the published research. A published third-party study in diet-induced obese mice found that NCT-treated mice gained 30 to 40% less weight than untreated mice on the same diet at equal caloric intake.

Two small, short, randomized, placebo-controlled human studies by third parties used a blend of NCT and a related molecule, NFT, and met their primary endpoints. To be clear, we did not conduct these studies. They were performed by others and used a blend of NCT and NFT rather than our pure NCT, and their results may not be predictive of results with our product. Separately, a published 90-day toxicology study supports an estimated safe intake of approximately 992 milligrams per day for a 70-kilogram adult, which we intend to use in our GRAS determination.

Turning now to our pipeline: our supplement programs carry gemstone codenames. AMBER, based on NCT, has completed discovery and proof of concept and is now in scale-up, with GRAS work and clinical studies planned in parallel. SAPPHIRE, for joint comfort, has completed proof of concept and begun scale-up. AMETHYST, for mental stress, focus, and energy, has completed proof of concept. We're also evaluating a women's health program focused on menopause support, and have screened and scored more than 50 additional molecules with potential to support human health.

On the pharmaceutical side, our candidates are engineered analogs, including NCT analogs and NIH grant-funded cannabinoid analogs. All are in discovery or lead optimization, and none has begun IND-enabling studies or clinical trials.

Finally, with regard to intellectual property: as of November 11, 2026, we owned or exclusively licensed 14 patent families, comprising 29 issued patents, 3 allowed applications, and 49 pending applications in the United States, Europe, and 13 other countries and territories. Our NCT process patent application is pending and may not issue.

With that, I'll hand it over to Damien to walk through manufacturing and commercialization.

 

Manufacturing, regulatory path and commercialization

Damien Perriman: Thank you, Tyler. Today I'm going to walk you through a manufacturing, regulatory, and commercialization update.

In September, we selected Curia Global as our commercial-scale manufacturing partner for Tyferyn. Curia will perform the full process: enzyme fermentation at its facility in León, Spain, and the cell-free reaction and purification at its facility in Rozzano, Italy. Technology transfer began in the fourth quarter, building toward larger-scale production in 2027. We do not plan to build our own manufacturing facilities, keeping this an asset-light commercialization journey.

On the regulatory path, we intend to market Tyferyn as a dietary supplement ingredient. Claims will be limited to structure/function statements, with no disease claims at any stage. The path has three elements:

One development we are watching closely: the FDA published a proposed rule on August 11, 2026, that would require FDA notification of future GRAS determinations. If it is finalized, our regulatory path and timeline may change.

On commercialization, we intend to commercialize Tyferyn through one or more of three channels: first, ingredient sales to supplement brands and formulators, including through offtake agreements; second, our own direct-to-consumer brand, potentially through a joint venture or other co-owned structure; and third, marketing alliances across online and, once sales velocity is established, retail channels.

We plan to fully own the Tyferyn technology through the GRAS determination and the Curia technology transfer and, at the same time or after those milestones, either partner or take Tyferyn to market ourselves. The structure of any partnership or spin-out has not yet been determined.

To be clear, the NCT launch timeline depends on Curia completing our scale-up and technology transfer, on our securing a market launch partner, which we have not yet done, and on regulatory requirements in the markets where NCT will be sold.

Thank you. And now Fouad will take you through the financials.

 

Third quarter 2026 financial results

Fouad Nawaz: Thank you, Damien, and good afternoon, everyone. I will provide a summary of our financial results as reported in our unaudited third quarter Form 10-Q, which was filed on November 13.

Our total operating costs for the third quarter were $3.05 million, compared with $2.52 million in the third quarter of 2025. Research and development costs, net of grant reimbursements, were $1.62 million versus $1.22 million, reflecting increased program activity. General and administrative costs were $1.43 million versus $1.31 million in 2025.

The net loss for the quarter was $2.24 million, or $0.24 per share, compared with $2.29 million, or $0.27 per share, a year ago. I want to be clear that the net loss is lower than last year only because of a non-cash gain of $0.77 million from the change in fair value of warrant liabilities related to our June offering. Our overall operating loss did increase.

For the nine months, the net loss was $7.49 million, compared with $6.50 million in 2025, and cash used in operating activities was $5.39 million, compared with $4.53 million in the same period of 2025.

We ended September with $3.26 million in cash and cash equivalents, which will provide us sufficient liquidity to support ongoing operations and key initiatives into the beginning of 2027. We continue to be disciplined in our spending approach and to ensure capital is allocated efficiently to maximize shareholder value. Additionally, we continue to explore non-dilutive funding opportunities, strategic partnerships, and potential government grants to further strengthen our financial position.

With that, I will pass the call back to Michael.

 

Closing remarks

Michael Heltzen: Thank you, team. To summarize the quarter: we selected Curia as our commercial-scale manufacturing partner and began the technology transfer; we were selected for the DOE Genesis Mission; and we continue to advance the NCT regulatory work, with a single-dose human PK study targeted to be communicated in the first quarter of 2027 and a GRAS determination targeted for the second quarter of 2027. Those targets depend on factors we have described today, and we will keep reporting progress as it happens.

That concludes today's update. Thank you very much for your support and continued interest.

 

 eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “potential,” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of eXoZymes’ quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.